Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates

Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules we...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 63; no. 17; pp. 9603 - 9622
Main Authors Staben, Leanna R, Chen, Jinhua, Cruz-Chuh, Josefa dela, del Rosario, Geoff, Go, Mary Ann, Guo, Jun, Khojasteh, S. Cyrus, Kozak, Katherine R, Li, Guangmin, Ng, Carl, Lewis Phillips, Gail D, Pillow, Thomas H, Rowntree, Rebecca K, Wai, John, Wei, BinQing, Xu, Keyang, Xu, Zijin, Yu, Shang-Fan, Zhang, Donglu, Dragovich, Peter S
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 10.09.2020
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group.
AbstractList Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group.Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group.
Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and in vitro antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of in vitro and in vivo experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group.
Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently in clinical development. In order to further explore this ADC payload class, the physicochemical properties of various PBD-dimer molecules were modified by the systematic introduction of acidic and basic moieties into their chemical structures. The impact of these changes on DNA binding, cell membrane permeability, and antiproliferation potency was, respectively, determined using a DNA alkylation assay, PAMPA assessments, and cell-based cytotoxicity measurements conducted with a variety of cancer lines. The modified PBD-dimer compounds were subsequently incorporated into CD22-targeting ADCs, and these entities were profiled in a variety of and experiments. The introduction of a strongly basic moiety into the PBD-dimer scaffold afforded a conjugate with dramatically worsened mouse tolerability properties relative to ADCs derived from related payloads, which lacked the basic group.
Author Chen, Jinhua
Wai, John
Zhang, Donglu
Kozak, Katherine R
Cruz-Chuh, Josefa dela
Lewis Phillips, Gail D
Go, Mary Ann
Yu, Shang-Fan
Staben, Leanna R
Xu, Zijin
Xu, Keyang
Ng, Carl
Pillow, Thomas H
del Rosario, Geoff
Dragovich, Peter S
Wei, BinQing
Khojasteh, S. Cyrus
Guo, Jun
Rowntree, Rebecca K
Li, Guangmin
AuthorAffiliation Genentech, Inc
WuXi AppTec Co., Ltd
AuthorAffiliation_xml – name: Genentech, Inc
– name: WuXi AppTec Co., Ltd
Author_xml – sequence: 1
  givenname: Leanna R
  surname: Staben
  fullname: Staben, Leanna R
  organization: Genentech, Inc
– sequence: 2
  givenname: Jinhua
  surname: Chen
  fullname: Chen, Jinhua
  organization: WuXi AppTec Co., Ltd
– sequence: 3
  givenname: Josefa dela
  surname: Cruz-Chuh
  fullname: Cruz-Chuh, Josefa dela
  organization: Genentech, Inc
– sequence: 4
  givenname: Geoff
  surname: del Rosario
  fullname: del Rosario, Geoff
  organization: Genentech, Inc
– sequence: 5
  givenname: Mary Ann
  surname: Go
  fullname: Go, Mary Ann
  organization: Genentech, Inc
– sequence: 6
  givenname: Jun
  surname: Guo
  fullname: Guo, Jun
  organization: Genentech, Inc
– sequence: 7
  givenname: S. Cyrus
  surname: Khojasteh
  fullname: Khojasteh, S. Cyrus
  organization: Genentech, Inc
– sequence: 8
  givenname: Katherine R
  surname: Kozak
  fullname: Kozak, Katherine R
  organization: Genentech, Inc
– sequence: 9
  givenname: Guangmin
  surname: Li
  fullname: Li, Guangmin
  organization: Genentech, Inc
– sequence: 10
  givenname: Carl
  surname: Ng
  fullname: Ng, Carl
  organization: Genentech, Inc
– sequence: 11
  givenname: Gail D
  surname: Lewis Phillips
  fullname: Lewis Phillips, Gail D
  organization: Genentech, Inc
– sequence: 12
  givenname: Thomas H
  surname: Pillow
  fullname: Pillow, Thomas H
  organization: Genentech, Inc
– sequence: 13
  givenname: Rebecca K
  surname: Rowntree
  fullname: Rowntree, Rebecca K
  organization: Genentech, Inc
– sequence: 14
  givenname: John
  surname: Wai
  fullname: Wai, John
  organization: WuXi AppTec Co., Ltd
– sequence: 15
  givenname: BinQing
  surname: Wei
  fullname: Wei, BinQing
  organization: Genentech, Inc
– sequence: 16
  givenname: Keyang
  surname: Xu
  fullname: Xu, Keyang
  organization: Genentech, Inc
– sequence: 17
  givenname: Zijin
  surname: Xu
  fullname: Xu, Zijin
  organization: WuXi AppTec Co., Ltd
– sequence: 18
  givenname: Shang-Fan
  surname: Yu
  fullname: Yu, Shang-Fan
  organization: Genentech, Inc
– sequence: 19
  givenname: Donglu
  surname: Zhang
  fullname: Zhang, Donglu
  organization: Genentech, Inc
– sequence: 20
  givenname: Peter S
  orcidid: 0000-0001-7372-2862
  surname: Dragovich
  fullname: Dragovich, Peter S
  email: dragovich.peter@gene.com
  organization: Genentech, Inc
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32787101$$D View this record in MEDLINE/PubMed
BookMark eNqNUsGO0zAUtNAitlv4A4R8XIRSbMdNUm5Ld4GVVqISC9foxXlpXSV21naEsif-gf_go_gS3G3LgQNwsqWZefPsmTNyYqxBQp5zNuNM8Neg_GzbYa022M2YYixb8EdkwueCJbJg8oRMGBMiEZlIT8mZ91vGWMpF-oScpiIvcs74hPz4NPqAHQSt6BdwOl6sobahq9E529oKzb2tNdxjrw3S89Xby5fJpe7Q0RWMrYWarjaj18ru9tAKWrpytkcXNHp63fWggqdXTRMhNVIwNb21LTqodKvDuHMKG6RL6xz63ppamzW9MEFXth5_fvt-6YZ1RM12WENA_5Q8bqD1-OxwTsnnd1e3yw_Jzcf318uLmwQklyGpFFRpxlEsUoy-TS4hPjyvoRZVreYyrbio80iCeZFmgqHM55CKrJC5aBY5pFNyvp_bO3s3oA9lp73CtgWDdvClkKlkGSuiwZS8OFCHKsZR9k534Mby-MeR8GpP-IqVbbzSaBT-psVQ5jmXiziPMSkiu_h_9lKHh8CWdjAhSt_spcpZ7x02pTrgwYFuS87KXXPK2Jzy2Jzy0Jwoln-Ij57_kLG97AG1gzMxlr9LfgE2h98c
CitedBy_id crossref_primary_10_1038_s41467_023_44533_z
crossref_primary_10_1021_jacs_4c03529
crossref_primary_10_1039_D2NJ03037C
crossref_primary_10_1016_j_ejmech_2024_116233
crossref_primary_10_1021_acs_jcim_1c01130
crossref_primary_10_1038_s41392_022_00947_7
crossref_primary_10_1021_acs_bioconjchem_2c00611
crossref_primary_10_1002_advs_202306309
crossref_primary_10_1016_j_cell_2022_05_029
crossref_primary_10_1016_j_ejmech_2024_116709
crossref_primary_10_1016_j_ejmech_2024_116556
crossref_primary_10_1016_j_apsb_2023_06_015
Cites_doi 10.1016/j.yexmp.2010.01.006
10.1021/mp500762u
10.1158/1078-0432.CCR-18-1300
10.1158/1535-7163.MCT-18-1302
10.1002/anie.201200447
10.1126/scitranslmed.aac9459
10.1371/journal.pone.0146311
10.1021/bc0502917
10.1021/jm030897l
10.1038/s41375-018-0278-7
10.2174/1568026619666190401112517
10.1182/blood-2018-99-118198
10.1158/0008-5472.CAN-13-1436
10.1039/c1cs15071e
10.1002/anie.201510610
10.1016/j.molimm.2014.09.014
10.1021/acsmedchemlett.9b00310
10.1182/blood-2013-03-491506
10.1158/1535-7163.MCT-17-0296
10.1182/bloodadvances.2018020107
10.1021/jm970530e
10.1158/0008-5472.CAN-08-1776
10.1021/acsmedchemlett.6b00233
10.3390/ijms20051115
10.1158/1535-7163.MCT-16-0641
10.1182/blood-2018-99-118133
10.1055/s-1986-31738
10.1158/1535-7163.MCT-16-0233
10.1158/0008-5472.CAN-08-2250
10.1007/978-1-4939-9929-3_4
10.1016/S0960-894X(98)00609-X
10.1073/pnas.63.1.78
10.1158/1538-7445.AM2018-2792A
10.1158/1078-0432.CCR-18-0333
10.1021/acs.jmedchem.7b00736
10.1021/acs.jmedchem.5b00201
10.1021/bi901655t
10.3390/catal10040443
10.1111/cas.12966
10.1002/adsc.200303203
10.1158/0008-5472.CAN-05-4489
10.1021/acs.bioconjchem.5b00430
10.1021/acsmedchemlett.9b00240
10.1016/j.nucmedbio.2014.07.005
10.1021/ja101845m
10.1016/j.ejmech.2019.06.044
10.1158/0008-5472.CAN-15-1795
10.1021/bi034313t
10.1021/acs.bioconjchem.7b00791
ContentType Journal Article
DBID AAYXX
CITATION
17B
1KM
AOWDO
BLEPL
DTL
EGQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1021/acs.jmedchem.0c00691
DatabaseName CrossRef
Web of Knowledge
Index Chemicus
Web of Science - Science Citation Index Expanded - 2020
Web of Science Core Collection
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
Web of Science
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Web of Science
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 1KM
  name: Index Chemicus
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-4804
EndPage 9622
ExternalDocumentID 32787101
000571493400042
10_1021_acs_jmedchem_0c00691
c500932642
Genre Journal Article
GroupedDBID -
.K2
55A
5GY
5RE
5VS
7~N
AABXI
ABFLS
ABMVS
ABOCM
ABPTK
ABUCX
ACGFS
ACJ
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
DU5
EBS
ED
ED~
F5P
GNL
IH9
IHE
JG
JG~
K2
L7B
LG6
P2P
ROL
TN5
UI2
VF5
VG9
W1F
WH7
X
XFK
YZZ
ZY4
---
-~X
4.4
6P2
AAHBH
AAYXX
ABBLG
ABJNI
ABLBI
ABQRX
ACGFO
ADHLV
AGXLV
AHGAQ
CITATION
CUPRZ
GGK
IH2
XSW
YQT
17B
1KM
BLEPL
DTL
GROUPED_WOS_WEB_OF_SCIENCE
ABTAH
CGR
CUY
CVF
ECM
EIF
NPM
YIN
7X8
ID FETCH-LOGICAL-a414t-bcab361e293ecacf74a1237dad2bdc543b12d7caba583620e475a3268472f97a3
IEDL.DBID ACS
ISICitedReferencesCount 14
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000571493400042
ISSN 0022-2623
1520-4804
IngestDate Fri Jul 11 09:23:15 EDT 2025
Wed Feb 19 02:30:19 EST 2025
Fri Aug 29 16:12:15 EDT 2025
Wed Jul 09 16:15:16 EDT 2025
Thu Apr 24 22:59:42 EDT 2025
Tue Jul 01 01:09:51 EDT 2025
Sat Sep 12 13:17:16 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 17
Keywords CANCER-CELLS
TARGET
DIMER
POTENCY
DNA
CROSS-LINKING
RELEASE
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
LinkModel DirectLink
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-a414t-bcab361e293ecacf74a1237dad2bdc543b12d7caba583620e475a3268472f97a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-7372-2862
PMID 32787101
PQID 2434060829
PQPubID 23479
PageCount 20
ParticipantIDs crossref_primary_10_1021_acs_jmedchem_0c00691
pubmed_primary_32787101
webofscience_primary_000571493400042
webofscience_primary_000571493400042CitationCount
crossref_citationtrail_10_1021_acs_jmedchem_0c00691
acs_journals_10_1021_acs_jmedchem_0c00691
proquest_miscellaneous_2434060829
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
ACJ
VG9
W1F
ACS
AEESW
AFEFF
.K2
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-09-10
PublicationDateYYYYMMDD 2020-09-10
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-09-10
  day: 10
PublicationDecade 2020
PublicationPlace WASHINGTON
PublicationPlace_xml – name: WASHINGTON
– name: United States
PublicationTitle Journal of medicinal chemistry
PublicationTitleAbbrev J MED CHEM
PublicationTitleAlternate J. Med. Chem
PublicationYear 2020
Publisher American Chemical Society
Amer Chemical Soc
Publisher_xml – name: American Chemical Society
– name: Amer Chemical Soc
References ref17/cit17b
ref3/cit3
ref33/cit33a
ref17/cit17a
ref13/cit13a
ref13/cit13b
ref27/cit27a
ref12/cit12d
ref27/cit27b
ref12/cit12c
ref12/cit12b
ref12/cit12a
ref23/cit23
ref31/cit31
ref2/cit2
ref33/cit33b
ref34/cit34
ref37/cit37
ref20/cit20
ref26/cit26b
ref10/cit10
ref16/cit16b
ref35/cit35
ref36/cit36a
ref16/cit16a
ref36/cit36b
ref36/cit36c
ref19/cit19
ref21/cit21
ref22/cit22a
ref26/cit26a
ref22/cit22b
ref7/cit7b
ref7/cit7a
ref38/cit38
ref6/cit6
Phillips G. D. L. (ref27/cit27c) 2008; 68
ref18/cit18
ref9/cit9b
ref9/cit9a
ref11/cit11
ref25/cit25
ref29/cit29
ref8/cit8a
ref8/cit8b
ref32/cit32
ref14/cit14
ref5/cit5
Ohri R. (ref24/cit24) 2018; 29
ref28/cit28
ref15/cit15
ref30/cit30a
ref30/cit30b
ref4/cit4
ref1/cit1
Dubowchik, GM (WOS:000077485600013) 1998; 8
Maderna, A (WOS:000355637900011) 2015; 12
Shor, B (WOS:000361922200011) 2015; 67
Ohri, R (WOS:000426144300029) 2018; 29
Choi, J (WOS:000343614800005) 2014; 41
Ogitani, Y (WOS:000384724100022) 2016; 107
Smith, DA (WOS:000359683700001) 2015; 58
Kansy, M (WOS:000072852600001) 1998; 41
Chinchilla, R (WOS:000295037400015) 2011; 40
Zhang, DL (WOS:000387739200005) 2016; 7
Polson, AG (WOS:000264541300028) 2009; 69
EDELMAN, GM (WOS:A1969D694400015) 1969; 63
Erickson, HK (WOS:000236843200060) 2006; 66
Smellie, M (WOS:000184100200014) 2003; 42
Widdison, WC (WOS:000365148700011) 2015; 26
Sutherland, MSK (WOS:000323394300023) 2013; 122
Rettig, M (WOS:000272852100017) 2009; 48
(000571493400042.1) 2018
Li, GM (WOS:000437274600008) 2018; 17
Gschwantler-Kaulich, D (WOS:000367805100041) 2016; 11
Saunders, LR (WOS:000360942300007) 2015; 7
Gregson, SJ (WOS:000486133100043) 2019; 179
Zammarchi, F (WOS:000468819500159) 2018; 78
Adhikari, P (WOS:000561051100005) 2020; 2078
Loomis, K (WOS:000276741000004) 2010; 88
Zheng, B (WOS:000458739900026) 2019; 25
Gregson, SJ (WOS:000418393100006) 2017; 60
Cailleau, T (WOS:000472149500009) 2019; 19
Sookcharoenpinyo, B (WOS:000303506800012) 2012; 51
Caimi, P (WOS:000454842800074) 2018; 132
Hamadani, M (WOS:000454837602304) 2018; 132
Kinneer, K. (000571493400042.24) 2019; 130
Hingorani, DV (WOS:000505667900014) 2020; 19
Costoplus, JA (WOS:000490355900005) 2019; 10
Pillow, TH (WOS:000400713500010) 2017; 16
Kanwal, I (WOS:000537227400008) 2020; 10
Li, F (WOS:000375332300021) 2016; 76
Doronina, SO (WOS:000234905500016) 2006; 17
Phillips, GDL (WOS:000261136600024) 2008; 68
Gregson, SJ (WOS:000189151500011) 2004; 47
Kinneer, K (WOS:000453267600046) 2018; 24
Tohma, H (WOS:000220763400003) 2004; 346
Mantaj, J (WOS:000394996100004) 2017; 56
Rinnerthaler, G (WOS:000462542300114) 2019; 20
DUCHENE, KH (WOS:A1986D711300019) 1986
Reid, EE (WOS:000480500000016) 2019; 10
Jiang, YP (WOS:000439597400008) 2018; 2
Flynn, MJ (WOS:000387546300015) 2016; 15
Pop, LM (WOS:000329297600026) 2014; 74
Dash, BP (WOS:000277445400051) 2010; 132
References_xml – ident: ref25/cit25
  doi: 10.1016/j.yexmp.2010.01.006
– ident: ref12/cit12b
  doi: 10.1021/mp500762u
– ident: ref16/cit16b
  doi: 10.1158/1078-0432.CCR-18-1300
– ident: ref12/cit12d
  doi: 10.1158/1535-7163.MCT-18-1302
– ident: ref36/cit36c
  doi: 10.1002/anie.201200447
– ident: ref4/cit4
  doi: 10.1126/scitranslmed.aac9459
– volume: 29
  start-page: 473
  volume-title: Bioconjugate Chem.
  year: 2018
  ident: ref24/cit24
– ident: ref30/cit30a
  doi: 10.1371/journal.pone.0146311
– ident: ref12/cit12a
  doi: 10.1021/bc0502917
– ident: ref17/cit17b
  doi: 10.1021/jm030897l
– ident: ref8/cit8a
  doi: 10.1038/s41375-018-0278-7
– ident: ref16/cit16a
  doi: 10.2174/1568026619666190401112517
– ident: ref9/cit9b
  doi: 10.1182/blood-2018-99-118198
– ident: ref11/cit11
– ident: ref30/cit30b
  doi: 10.1158/0008-5472.CAN-13-1436
– ident: ref33/cit33b
  doi: 10.1039/c1cs15071e
– ident: ref1/cit1
  doi: 10.1002/anie.201510610
– ident: ref26/cit26a
  doi: 10.1016/j.molimm.2014.09.014
– ident: ref13/cit13b
  doi: 10.1021/acsmedchemlett.9b00310
– ident: ref5/cit5
  doi: 10.1182/blood-2013-03-491506
– ident: ref27/cit27b
  doi: 10.1158/1535-7163.MCT-17-0296
– ident: ref22/cit22b
  doi: 10.1182/bloodadvances.2018020107
– ident: ref20/cit20
  doi: 10.1021/jm970530e
– volume: 68
  start-page: 9280
  year: 2008
  ident: ref27/cit27c
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-1776
– ident: ref19/cit19
  doi: 10.1021/acsmedchemlett.6b00233
– ident: ref27/cit27a
  doi: 10.3390/ijms20051115
– ident: ref3/cit3
  doi: 10.1158/1535-7163.MCT-16-0641
– ident: ref6/cit6
  doi: 10.1182/blood-2018-99-118133
– ident: ref36/cit36a
  doi: 10.1055/s-1986-31738
– ident: ref37/cit37
– ident: ref9/cit9a
  doi: 10.1158/1535-7163.MCT-16-0233
– ident: ref26/cit26b
  doi: 10.1158/0008-5472.CAN-08-2250
– ident: ref34/cit34
  doi: 10.1007/978-1-4939-9929-3_4
– ident: ref21/cit21
  doi: 10.1016/S0960-894X(98)00609-X
– ident: ref10/cit10
– ident: ref23/cit23
  doi: 10.1073/pnas.63.1.78
– ident: ref7/cit7a
  doi: 10.1158/1538-7445.AM2018-2792A
– ident: ref2/cit2
  doi: 10.1158/1078-0432.CCR-18-0333
– ident: ref18/cit18
  doi: 10.1021/acs.jmedchem.7b00736
– ident: ref31/cit31
  doi: 10.1021/acs.jmedchem.5b00201
– ident: ref38/cit38
  doi: 10.1021/bi901655t
– ident: ref33/cit33a
  doi: 10.3390/catal10040443
– ident: ref14/cit14
  doi: 10.1111/cas.12966
– ident: ref35/cit35
  doi: 10.1002/adsc.200303203
– ident: ref29/cit29
  doi: 10.1158/0008-5472.CAN-05-4489
– ident: ref13/cit13a
  doi: 10.1021/acs.bioconjchem.5b00430
– ident: ref15/cit15
  doi: 10.1021/acsmedchemlett.9b00240
– ident: ref7/cit7b
– ident: ref32/cit32
  doi: 10.1016/j.nucmedbio.2014.07.005
– ident: ref36/cit36b
  doi: 10.1021/ja101845m
– ident: ref22/cit22a
  doi: 10.1016/j.ejmech.2019.06.044
– ident: ref28/cit28
  doi: 10.1158/1078-0432.CCR-18-1300
– ident: ref8/cit8b
– ident: ref12/cit12c
  doi: 10.1158/0008-5472.CAN-15-1795
– ident: ref17/cit17a
  doi: 10.1021/bi034313t
– volume: 29
  start-page: 473
  year: 2018
  ident: WOS:000426144300029
  article-title: High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers
  publication-title: BIOCONJUGATE CHEMISTRY
  doi: 10.1021/acs.bioconjchem.7b00791
– volume: 63
  start-page: 78
  year: 1969
  ident: WOS:A1969D694400015
  article-title: COVALENT STRUCTURE OF AN ENTIRE GAMMAG IMMUNOGLOBULIN MOLECULE
  publication-title: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
– volume: 179
  start-page: 591
  year: 2019
  ident: WOS:000486133100043
  article-title: Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual beta-glucuronide and dipeptide triggers
  publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1016/j.ejmech.2019.06.044
– volume: 66
  start-page: 4426
  year: 2006
  ident: WOS:000236843200060
  article-title: Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
  publication-title: CANCER RESEARCH
  doi: 10.1158/0008-5472.CAN-05-4489
– volume: 25
  start-page: 1358
  year: 2019
  ident: WOS:000458739900026
  article-title: An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia
  publication-title: CLINICAL CANCER RESEARCH
  doi: 10.1158/1078-0432.CCR-18-0333
– volume: 2078
  start-page: 51
  year: 2020
  ident: WOS:000561051100005
  article-title: Site-Specific Conjugation to Cys-Engineered THIOMAB (TM) Antibodies
  publication-title: ANTIBODY-DRUG CONJUGATES: METHODS AND PROTOCOLS
  doi: 10.1007/978-1-4939-9929-3_4
– start-page: 659
  year: 1986
  ident: WOS:A1986D711300019
  article-title: A HYDROCARBON SKELETON WITH 12 IDENTICAL FUNCTIONAL-GROUPS - SYNTHESIS OF A DODECA HOST COMPOUND
  publication-title: SYNTHESIS-STUTTGART
– volume: 78
  year: 2018
  ident: WOS:000468819500159
  article-title: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors
  publication-title: CANCER RESEARCH
  doi: 10.1158/1538-7445.AM2018-2792A
– volume: 10
  start-page: 1193
  year: 2019
  ident: WOS:000480500000016
  article-title: Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs)
  publication-title: ACS MEDICINAL CHEMISTRY LETTERS
  doi: 10.1021/acsmedchemlett.9b00240
– volume: 40
  start-page: 5084
  year: 2011
  ident: WOS:000295037400015
  article-title: Recent advances in Sonogashira reactions
  publication-title: CHEMICAL SOCIETY REVIEWS
  doi: 10.1039/c1cs15071e
– volume: 48
  start-page: 12223
  year: 2009
  ident: WOS:000272852100017
  article-title: Solution Structure of a Covalently Bound Pyrrolo[2,1-c][1,4]benzodiazepine-Benzimidazole Hybrid to a 10mer DNA Duplex
  publication-title: BIOCHEMISTRY
  doi: 10.1021/bi901655t
– volume: 41
  start-page: 1007
  year: 1998
  ident: WOS:000072852600001
  article-title: Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
– volume: 58
  start-page: 5691
  year: 2015
  ident: WOS:000359683700001
  article-title: Volume of Distribution in Drug Design
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.5b00201
– volume: 130
  year: 2019
  ident: 000571493400042.24
  article-title: Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma
  publication-title: Leukemia
– volume: 69
  start-page: 2358
  year: 2009
  ident: WOS:000264541300028
  article-title: Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
  publication-title: CANCER RESEARCH
  doi: 10.1158/0008-5472.CAN-08-2250
– volume: 56
  start-page: 462
  year: 2017
  ident: WOS:000394996100004
  article-title: From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
  publication-title: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
  doi: 10.1002/anie.201510610
– volume: 107
  start-page: 1039
  year: 2016
  ident: WOS:000384724100022
  article-title: Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
  publication-title: CANCER SCIENCE
  doi: 10.1111/cas.12966
– volume: 68
  start-page: 9280
  year: 2008
  ident: WOS:000261136600024
  article-title: Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
  publication-title: CANCER RESEARCH
  doi: 10.1158/0008-5472.CAN-08-1776
– volume: 11
  start-page: ARTN e0146311
  year: 2016
  ident: WOS:000367805100041
  article-title: HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0146311
– volume: 8
  start-page: 3341
  year: 1998
  ident: WOS:000077485600013
  article-title: Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin
  publication-title: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
– volume: 10
  start-page: 1393
  year: 2019
  ident: WOS:000490355900005
  article-title: Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing
  publication-title: ACS MEDICINAL CHEMISTRY LETTERS
  doi: 10.1021/acsmedchemlett.9b00310
– volume: 346
  start-page: 111
  year: 2004
  ident: WOS:000220763400003
  article-title: Hypervalent iodine reagents for the oxidation of alcohols and their application to complex molecule synthesis
  publication-title: ADVANCED SYNTHESIS & CATALYSIS
  doi: 10.1002/adsc.200303203
– volume: 74
  start-page: 263
  year: 2014
  ident: WOS:000329297600026
  article-title: A Reevaluation of CD22 Expression in Human Lung Cancer
  publication-title: CANCER RESEARCH
  doi: 10.1158/0008-5472.CAN-13-1436
– volume: 7
  start-page: 988
  year: 2016
  ident: WOS:000387739200005
  article-title: Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates
  publication-title: ACS MEDICINAL CHEMISTRY LETTERS
  doi: 10.1021/acsmedchemlett.6b00233
– volume: 41
  start-page: 802
  year: 2014
  ident: WOS:000343614800005
  article-title: N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: Influence of isomeric substitution on radiolabeling and target cell residualization
  publication-title: NUCLEAR MEDICINE AND BIOLOGY
  doi: 10.1016/j.nucmedbio.2014.07.005
– volume: 15
  start-page: 2709
  year: 2016
  ident: WOS:000387546300015
  article-title: ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
  publication-title: MOLECULAR CANCER THERAPEUTICS
  doi: 10.1158/1535-7163.MCT-16-0233
– volume: 17
  start-page: 1441
  year: 2018
  ident: WOS:000437274600008
  article-title: Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
  publication-title: MOLECULAR CANCER THERAPEUTICS
  doi: 10.1158/1535-7163.MCT-17-0296
– volume: 42
  start-page: 8232
  year: 2003
  ident: WOS:000184100200014
  article-title: Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: Kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers
  publication-title: BIOCHEMISTRY
  doi: 10.1021/bi034313t
– volume: 24
  start-page: 6570
  year: 2018
  ident: WOS:000453267600046
  article-title: SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
  publication-title: CLINICAL CANCER RESEARCH
  doi: 10.1158/1078-0432.CCR-18-1300
– volume: 47
  start-page: 1161
  year: 2004
  ident: WOS:000189151500011
  article-title: Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8 ' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm030897l
– year: 2018
  ident: 000571493400042.1
  article-title: Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
  publication-title: International patent application
– volume: 19
  start-page: 157
  year: 2020
  ident: WOS:000505667900014
  article-title: Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability
  publication-title: MOLECULAR CANCER THERAPEUTICS
  doi: 10.1158/1535-7163.MCT-18-1302
– volume: 2
  start-page: 1738
  year: 2018
  ident: WOS:000439597400008
  article-title: CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia
  publication-title: BLOOD ADVANCES
  doi: 10.1182/bloodadvances.2018020107
– volume: 10
  start-page: ARTN 443
  year: 2020
  ident: WOS:000537227400008
  article-title: Palladium and Copper Catalyzed Sonogashira cross Coupling an Excellent Methodology for C-C Bond Formation over 17 Years: A Review
  publication-title: CATALYSTS
  doi: 10.3390/catal10040443
– volume: 7
  start-page: ARTN 302ra136
  year: 2015
  ident: WOS:000360942300007
  article-title: A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
  publication-title: SCIENCE TRANSLATIONAL MEDICINE
  doi: 10.1126/scitranslmed.aac9459
– volume: 132
  year: 2018
  ident: WOS:000454842800074
  article-title: Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study
  publication-title: BLOOD
  doi: 10.1182/blood-2018-99-118133
– volume: 60
  start-page: 9490
  year: 2017
  ident: WOS:000418393100006
  article-title: Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.7b00736
– volume: 12
  start-page: 1798
  year: 2015
  ident: WOS:000355637900011
  article-title: Recent Advances in the Development of New Auristatins: Structural Modifications and Application in Antibody Drug Conjugates
  publication-title: MOLECULAR PHARMACEUTICS
  doi: 10.1021/mp500762u
– volume: 20
  start-page: ARTN 1115
  year: 2019
  ident: WOS:000462542300114
  article-title: HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
  publication-title: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
  doi: 10.3390/ijms20051115
– volume: 122
  start-page: 1455
  year: 2013
  ident: WOS:000323394300023
  article-title: SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
  publication-title: BLOOD
  doi: 10.1182/blood-2013-03-491506
– volume: 17
  start-page: 114
  year: 2006
  ident: WOS:000234905500016
  article-title: Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
  publication-title: BIOCONJUGATE CHEMISTRY
  doi: 10.1021/bc0502917
– volume: 51
  start-page: 4586
  year: 2012
  ident: WOS:000303506800012
  article-title: High-Affinity Disaccharide Binding by Tricyclic Synthetic Lectins
  publication-title: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
  doi: 10.1002/anie.201200447
– volume: 88
  start-page: 238
  year: 2010
  ident: WOS:000276741000004
  article-title: Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv
  publication-title: EXPERIMENTAL AND MOLECULAR PATHOLOGY
  doi: 10.1016/j.yexmp.2010.01.006
– volume: 132
  start-page: 6578
  year: 2010
  ident: WOS:000277445400051
  article-title: Synthesis and Properties of Carborane-Appended C-3-Symmetrical Extended pi Systems
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
  doi: 10.1021/ja101845m
– volume: 67
  start-page: 107
  year: 2015
  ident: WOS:000361922200011
  article-title: Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
  publication-title: MOLECULAR IMMUNOLOGY
  doi: 10.1016/j.molimm.2014.09.014
– volume: 19
  start-page: 741
  year: 2019
  ident: WOS:000472149500009
  article-title: Potentiation of PBD Dimers by Lipophilicity Manipulation
  publication-title: CURRENT TOPICS IN MEDICINAL CHEMISTRY
  doi: 10.2174/1568026619666190401112517
– volume: 76
  start-page: 2710
  year: 2016
  ident: WOS:000375332300021
  article-title: Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
  publication-title: CANCER RESEARCH
  doi: 10.1158/0008-5472.CAN-15-1795
– volume: 26
  start-page: 2261
  year: 2015
  ident: WOS:000365148700011
  article-title: Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing
  publication-title: BIOCONJUGATE CHEMISTRY
  doi: 10.1021/acs.bioconjchem.5b00430
– volume: 16
  start-page: 871
  year: 2017
  ident: WOS:000400713500010
  article-title: Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody-Drug Conjugates with Self-Immolative Disulfide Linkers
  publication-title: MOLECULAR CANCER THERAPEUTICS
  doi: 10.1158/1535-7163.MCT-16-0641
– volume: 132
  year: 2018
  ident: WOS:000454837602304
  article-title: Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma
  publication-title: BLOOD
  doi: 10.1182/blood-2018-99-118198
SSID ssj0003123
Score 2.4120502
Snippet Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody–drug conjugates (ADCs), and many examples are currently...
Cytotoxic pyrrolobenzodiazepine (PBD)-dimer molecules are frequently utilized as payloads for antibody-drug conjugates (ADCs), and many examples are currently...
Source Web of Science
SourceID proquest
pubmed
webofscience
crossref
acs
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 9603
SubjectTerms Benzodiazepines - chemistry
Binding Sites
Cell Line, Tumor
Cell Proliferation - drug effects
Chemical Phenomena
Chemistry, Medicinal
Dimerization
DNA - chemistry
DNA - metabolism
Humans
Immunoconjugates - adverse effects
Immunoconjugates - chemistry
Immunoconjugates - metabolism
Immunoconjugates - pharmacology
Life Sciences & Biomedicine
Models, Molecular
Nucleic Acid Conformation
Pharmacology & Pharmacy
Pyrroles - chemistry
Safety
Science & Technology
Title Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates
URI http://dx.doi.org/10.1021/acs.jmedchem.0c00691
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000571493400042
https://www.ncbi.nlm.nih.gov/pubmed/32787101
https://www.proquest.com/docview/2434060829
Volume 63
WOS 000571493400042
WOSCitedRecordID wos000571493400042
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZQOcCFR3mFl4xUVVRqtontXZNjybYqSECkblFvkR070NImqyR72D3xH_gf_Ch-CTNOsgsU1HJNbOcx45lvbM83hGzk0oxyJSPf5Ln1hQqUr4aC-1mUCTmKNM8VZiO_ez86OBJvj4fHq0Dxzx18Fu6orB6c4mHFz_Z8EGRIrQvRznU2gnmMUCg-XFpeHjLes4Mz8Ot9qtw_RkGHlNW_O6QLKPOvDsk5n_3b5EOfwtOeOfkymDV6kC0uMjpe8bvukFsdDqW7reLcJddssU5uxH35t3WymbSk1vNtOlnlaNXbdJMmK7rr-T3y_XBJBk0_QuTtRE3LnCbzqirxMEexKEELF3YKiJa-TF6Pt_zxybmtaILLBcpQdww1w9pdjryAJrhDUCHVK33jsjhruodUF_A2VBWGTsozeCN3rHeOTwIQS2NXZmRauiwduls0J7o08x9fv42r2Se4W5zOcMWwvk-O9vcm8YHfVYHwlQhF4-tMaT4KLeASC8_JpVAgZmmUYdpkoFc6ZEZCIzV8Bd44sEIOFUcSG8nySCr-gKwVZWEfEQrmJsh5NIyMttAPoJlQkdKWQ5QrmJYe2QKppN0srlO3Qc_C1F3sRJV2ovII79UmzTo6dazqcXZJL3_Za9rSiVzS_kWvkSnIHzdzVGHLWZ0ywQGLYWa0Rx62qrockTMww2BrPbLxq-4u7yNQlxAawwhotD0SXqVZ3H0lkiU0j__jVz0hNxmuUmDhjeApWWuqmX0GUK7Rz938_QlAREqE
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwELYQPdBLH_S1fboSQkUiS2I76-a43QUtLaBILIhbZCdOC4VklWQPu6f-h_6P_qj-ks54k2yfolwT23Eyk5nP9sw3hGykMumlSgZOkqbGEcpVjvIFd-IgFrIXaJ4qzEY-POqNTsT7M_9shfhNLgxMooSRSnuIv2QX8Hbw2gXGLH4yV103RoZdWPTcAjzCULH7g-PWAHOP8YYknIF7bzLm_jEK-qW4_NUv_QE2_-qXrA_au0tO29nb0JPP3Wmlu_H8N2LHG7_ePXKnRqW0v1Cj-2TFZOtkbdAUg1snm-GC4nq2TcfLjK1ym27ScEl-PXtAvh231ND0FNbhVvA0T2k4K4ocQzuyeQ46OTcTwLf0TfhuuOUMz69MQUPcPFAJtUGpMVbyslQGNMTzggKJX-m-zeks6S4SX8BsqMoSOs4vYUY2yHeGTwJISwe26Mgktzk7tJ9V5zpPZt-_fB0W049wN7uY4v5h-ZCc7O2OByOnrgnhKOGJytGx0rznGUApBp6TSqFA2jJRCdNJDFqmPZZIaKT8t-CbXSOkrzhS2kiWBlLxR2Q1yzPzhFAwPm7KAz9ItIF-ANSECpQ2HNa8gmnZIVsglaj-p8vIHtczL7IXa1FFtag6hDfaE8U1uTrW-Li8ppfT9posyEWuaf-6UcwI5I9HOyoz-bSMmOCAzDBPukMeLzS2HZEzMMpgeTtk42cVbu8jbJewUIYR0IR3iPc_zQb1WyJ1QvX0Bp_qFVkbjQ8PooP9ow_PyG2G-xdYksN9TlarYmpeAMir9Ev7S_8AFu9S5Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZQkYALj_IKTyNVFZWaJbG9a3JcdrtqeVSRukVVL5EdO9DSJqske9g98R_4H_wofgkz3mxaXipwTWzHzoxnxp6ZbwhZy6TpZUpGvsky6wsVKF91BffTKBWyF2meKcxGfrfb294Xrw-6B-dKfcEkKhipck583NUTkzUIA-ELfH6McYsf7WknSBFlFw4-l9Fzh8zdH-y1QpiHjC-Bwhmo-GXW3B9GQd2UVj_qpl8Mzt_qJqeHRjfIYbsCF37yqTOtdSed_wTu-F9LvEmuN9Yp7S_Y6Ra5ZPNVcnWwLAq3StbjBdT1bJOOzzK3qk26TuMzEOzZbfJ1r4WIpu_hPO4YgBYZjWdlWWCIRz4vgDfndgJ2Ln0evxpu-MOjU1vSGC8RlKEuODXFil4O0oDG6DcoEQCW7rjczopuIQAGzIaq3NBxcQIzcsG-M_wSmLZ04IqPTAqXu0P7eX2kCzP79vnLsJx-gLf58RTvEas7ZH-0NR5s-01tCF-JUNS-TpXmvdCCtWLhO5kUCigujTJMmxS4TYfMSGikui9BRwdWyK7iCG0jWRZJxe-SlbzI7X1CQQgFGY-6kdEW-oHBJlSktOVw9hVMS49sAFWSZm9XiXPbszBxDxtSJQ2pPMKXHJSkDcg61vo4uaCX3_aaLEBGLmj_bMmcCdAfXTwqt8W0SpjgYKFhvrRH7i24th2RMxDOIIE9snaejdv3aL5LODDDCCjKPRL-TbNBs0qEUKgf_MOvekquxMNR8nZn981Dco3hNQZW5ggekZW6nNrHYOvV-onb1d8BqCZVaA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systematic+Variation+of+Pyrrolobenzodiazepine+%28PBD%29-Dimer+Payload+Physicochemical+Properties+Impacts+Efficacy+and+Tolerability+of+the+Corresponding+Antibody%E2%80%93Drug+Conjugates&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Staben%2C+Leanna+R&rft.au=Chen%2C+Jinhua&rft.au=Cruz-Chuh%2C+Josefa+dela&rft.au=del+Rosario%2C+Geoff&rft.date=2020-09-10&rft.pub=American+Chemical+Society&rft.issn=0022-2623&rft.eissn=1520-4804&rft.volume=63&rft.issue=17&rft.spage=9603&rft.epage=9622&rft_id=info:doi/10.1021%2Facs.jmedchem.0c00691&rft.externalDocID=c500932642
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon